614
Participants
Start Date
April 25, 2017
Primary Completion Date
October 5, 2018
Study Completion Date
October 5, 2018
Danirixin
Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.
Danirixin matching placebo
Danirixin matching placebo will be available as white, film-coated, oval or round shaped tablets for oral administration.
Standard of care
Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.
Rescue medication
Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
GSK Investigational Site, Randwick
GSK Investigational Site, Westmead
GSK Investigational Site, Footscray
GSK Investigational Site, Clayton
GSK Investigational Site, Murdoch
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Großhansdorf
GSK Investigational Site, Morgantown
GSK Investigational Site, Greensboro
GSK Investigational Site, Madrid
GSK Investigational Site, Pozuelo de Alarcón/Madrid
GSK Investigational Site, Orangeburg
GSK Investigational Site, Spartanburg
GSK Investigational Site, Hanover
GSK Investigational Site, Birmingham
GSK Investigational Site, Birmingham
GSK Investigational Site, Salamanca
GSK Investigational Site, Santander
GSK Investigational Site, Zaragoza
GSK Investigational Site, Koblenz
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, St Louis
GSK Investigational Site, Darmstadt
GSK Investigational Site, Topeka
GSK Investigational Site, Medford
GSK Investigational Site, Râmnicu Vâlcea
GSK Investigational Site, Cluj-Napoca
GSK Investigational Site, Cluj-Napoca
GSK Investigational Site, Bacau
GSK Investigational Site, Focşani
GSK Investigational Site, Iași
GSK Investigational Site, Suceava
GSK Investigational Site, Constanța
GSK Investigational Site, Slobozia
GSK Investigational Site, Winnipeg
GSK Investigational Site, Truro
GSK Investigational Site, Toronto
GSK Investigational Site, Gatineau
GSK Investigational Site, Québec
GSK Investigational Site, Saint-Charles-Borromée
GSK Investigational Site, Leipzg
GSK Investigational Site, Alkmaar
GSK Investigational Site, Breda
GSK Investigational Site, Eindhoven
GSK Investigational Site, Hengelo
GSK Investigational Site, Hoorn
GSK Investigational Site, Ksawerów
GSK Investigational Site, Lubin
GSK Investigational Site, Ostrowiec Świętokrzyski
GSK Investigational Site, Szczecin
GSK Investigational Site, Wroclaw
GSK Investigational Site, Bucharest
GSK Investigational Site, Bucheon-Si, Gyeonggi-Do
GSK Investigational Site, Incheon
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Wonju-si, Gangwon-do
GSK Investigational Site, Barcelona
Lead Sponsor
GlaxoSmithKline
INDUSTRY